A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris

Trial Profile

A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Mar 2017

At a glance

  • Drugs Sarecycline (Primary)
  • Indications Acne vulgaris
  • Focus Adverse reactions
  • Sponsors Actavis
  • Most Recent Events

    • 23 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 30 Aug 2016 Planned End Date changed from 1 Nov 2016 to 1 Sep 2016.
    • 01 Dec 2015 Planned number of patients changed from 500 to 490 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top